Premium
Epidemiology of non‐gastroenteropancreatic (neuro)endocrine tumours
Author(s) -
Ferolla P.,
Faggiano A.,
Avenia N.,
Milone F.,
Masone S.,
Giampaglia F.,
Puma F.,
Daddi G.,
Angeletti G.,
Lombardi G.,
Santeusanio F.,
Colao A.
Publication year - 2007
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2006.02739.x
Subject(s) - neuroendocrine tumors , epidemiology , endocrine system , incidence (geometry) , pathology , medicine , bioinformatics , biology , hormone , physics , optics
Summary The widespread availability and reliability of immunohistochemical techniques in the last three decades have allowed researchers to identify cells with common neuroendocrine markers in virtually every organ. As a whole, these neuroendocrine cells form the so‐called diffuse neuroendocrine system. Tumours arising from the cells of the diffuse neuroendocrine system are defined as (neuro)endocrine tumours (NETs). NETs have been increasingly described in recent years. However, despite the increase in the number of published papers focused on NET, we still lack adequate epidemiological data, particularly for non‐gastroenteropancreatic (GEP) NETs. Furthermore, the real incidence of neuroendocrine differentiation for most sites is not completely known and is probably underestimated. As a consequence, data on the clinical features of many NET subgroups are not well known or confusing. For all of these reasons, we have attempted to evaluate the epidemiology of non‐GEP NETs, reviewing the limited data available in the literature.